New antivenom could save lives in remote areas

NCT ID NCT07659002

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 600 people in Ethiopia who receive a new type of snakebite antivenom called Premium-PANAF. The antivenom is freeze-dried, so it does not need refrigeration, making it easier to use in remote clinics. Researchers want to see if it safely stops the effects of snake venom and helps patients recover.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Premium-PANAF polyvalent snake antivenom

What this could lead to

If this antivenom proves safe and effective, it could become a standard treatment for snakebites in resource-limited areas, saving many lives.

What could go wrong

This is an observational study, not a controlled trial, so results may be less definitive. Allergic reactions or lack of effectiveness are possible risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SNAKE ENVENOMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Snake Bites snakebite envenomation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Abdurafi Health Center

    RECRUITING

    Ābderafī, Amhara, Ethiopia

    Contact Phone: •••-•••-•••• Email: •••••@•••••